Nanoform’s Clinical Study Indicates Positive Interim Results
Insider information Nanoform Finland Plc January 22[nd], 2021 at 08.10 a.m. Finnish time Nanoform’s Clinical Study Indicates Positive Interim Results Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful. Nanoform has received interim study results related to its Phase 1, Single-Centre, Part Crossover, Open-Label, Partially-Randomised Study Designed to Evaluate the